NasdaqGS:AMGNBiotechs
What Amgen (AMGN)'s Blocked Colorado Enbrel Price Cap Means For Shareholders
Earlier in July 2026, a federal judge blocked Colorado’s plan to impose a very large price cut on Amgen’s arthritis drug Enbrel, halting one of the most aggressive state-level attempts to cap branded drug prices.
This legal setback for Colorado reduces an important source of uncertainty around Enbrel’s pricing and puts a spotlight back on Amgen’s broader portfolio and policy exposure to future drug cost controls.
We’ll now examine how the blocked Colorado Enbrel price cap reshapes Amgen’s...